Skip to main content

Table 3 Local-regional progression-free survival in 120 stage IV NSCLC patients according to radiotherapy dose

From: Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Cycle Dose (Gy) No. Survival rate (%) Median survival (months) 95% confidence interval χ 2 p
1 year 2 year 3 year 5 year
2-3 <63 23 41.7 27.8 20.9 0 10 5.5 14.5 0.040 0.842
≥63 23 43.5 26.1 19.6 0 9 4.3 13.7
4-5 <63 18 32.6 21.7 0 0 9 6.6 11.4 9.217 0.002
≥63 56 77.4 36.2 27.2 15.9 20 16.5 23.5
\